Food and Drug Administration (FDA) Commissioner Margaret Hamburg reportedly testified before a House appropriations subcommittee about the effects of the across-the-board cuts imposed on the federal government and its agencies under the budgetary impasse known as the “sequester,” and said that the user fees collected from industry are also subject to sequestration. During the April 26, 2013, hearing, Hamburg indicated that the agency would be unable to spend all of the money without congressional authorization. The fees were apparently negotiated in exchange for FDA’s agreement to meet certain performance targets, and Hamburg said, “We aren’t going to be able to fully achieve the goals and performance targets.” She specifically cited guidance documents, timely new drug and device application reviews, staffing, and user fee programs as at-risk initiatives. Some $320 million in user fees and federal funding are reportedly affected by sequestration, and House member from both parties are evidently concerned about possible delays in the approval of life-saving medicines. See CQ HealthBeat News and Law360, April 26, 2013.